Loading stock…

Amdocs Limited (DOX) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

DOXAmdocs

Revenue FY25$4.5B

GROWTH RATING↗

WEAK25 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+50%9

EPS growth, FY27E+5%5

EPS growth, FY28E+5%5

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 5%/yr vs revenue 4%/yr).

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 75% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK27 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+13%9

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high71%3

1-year return-26%2

3-year return-25%2

5-year return-15%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+13%).

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-25% over three years and -15% over five), behind 70% of the market.

It's down 26% over the past year, now 29% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-25%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Amdocs. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DOXAmdocs

Revenue FY25$4.5B

GROWTH RATING↗

WEAK25 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+50%9

EPS growth, FY27E+5%5

EPS growth, FY28E+5%5

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 5%/yr vs revenue 4%/yr).

WATCH

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 75% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK27 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+13%9

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high71%3

1-year return-26%2

3-year return-25%2

5-year return-15%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+13%).

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-25% over three years and -15% over five), behind 70% of the market.

It's down 26% over the past year, now 29% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-25%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Amdocs. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Amdocs Limited

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Amdocs. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Amdocs. Get the full investment case.

Premium